Cargando…

546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital

BACKGROUND: Texas Children’s Hospital (TCH) implemented an outpatient clinic for eligible patients to receive infusions when COVID monoclonal antibodies (mAbs) were approved for use in non-hospitalized, high-risk patients with mild to moderate COVID-19. There are limited data evaluating the use of o...

Descripción completa

Detalles Bibliográficos
Autores principales: Stimes, Grant T, Rodriguez, Brittany, Gillispie, Amanda, Hilliard, Tanya J, Munoz, Flor M, Satter, Lisa Forbes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676883/
http://dx.doi.org/10.1093/ofid/ofad500.615
_version_ 1785149999070314496
author Stimes, Grant T
Rodriguez, Brittany
Gillispie, Amanda
Hilliard, Tanya J
Munoz, Flor M
Satter, Lisa Forbes
author_facet Stimes, Grant T
Rodriguez, Brittany
Gillispie, Amanda
Hilliard, Tanya J
Munoz, Flor M
Satter, Lisa Forbes
author_sort Stimes, Grant T
collection PubMed
description BACKGROUND: Texas Children’s Hospital (TCH) implemented an outpatient clinic for eligible patients to receive infusions when COVID monoclonal antibodies (mAbs) were approved for use in non-hospitalized, high-risk patients with mild to moderate COVID-19. There are limited data evaluating the use of outpatient COVID mAbs in pediatric patients. We describe the clinical characteristics and outcomes of the patients treated with COVID mAbs at TCH. METHODS: Patients that were referred to receive COVID mAbs from 12/1/2020 to 5/5/2022 were included. Information collected included demographics, comorbidities, refusal reason, adverse events, emergency center (EC) visits or admission within 14 days after final dose, and EC visit or admission within 14 days of referral if patients did not receive COVID mAbs. Chi-square was used to determine differences between the groups. RESULTS: There were 262 patients referred during the study period. The median age of all referred patients was 15.8 years (IQR 14-17.4 years). Majority of referrals were for treatment of COVID-19 infection rather than post-exposure prophylaxis (92.8% vs 7.2%). Of the 262 referrals, 134 patients received COVID mAbs (51.2%) while 128 patients were not treated. Majority of the patients received casirivimab-imdevimab (73.9%). The comorbidities of all patients are shown in Figure 1. The most common reasons for patients to not receive COVID mAbs were no drug available or not listed, and the full list of reasons are listed in Figure 2. The median time from reported symptom onset to infusion was 4 days (IQR 2-6 days). Of the 134 infused patients, 8 patients (6%) visited the EC within 14 days from infusion, and 6 (4.5%) were admitted while 4 patients (3.1%) that did not receive an antibody visited the EC resulting in 3 admissions (2.3%) (EC visits p=0.27; admissions p=0.34). There were 11 patients (8.2%) that experienced adverse events from their infusion, which led to 5 of the 8 EC visits. Comorbidities were similar across the infused and non-infused groups (p=0.16). [Figure: see text] Number of high-risk conditions represented by all referred, high-risk patients [Figure: see text] Number of patients for each reason for not receiving a COVID-19 antibody infusion CONCLUSION: COVID mAb treatments were well tolerated among pediatric patients. Majority of patients in both groups did not require EC visit or hospitalization. More data are needed to determine the clinical efficacy of mAbs patients. DISCLOSURES: Flor M. Munoz, MD, MSc, CDC respiratory virus surveillance: Grant/Research Support|Gilead: Grant/Research Support|Moderna, sanofi, aztra zeneca, Merck, GSK: Advisor/Consultant|NIH: DSMB|NIH COVID-19 vaccines in pregnancy: Grant/Research Support|Pfizer Pediatric COVID-19 vaccines: Grant/Research Support|Pfizer, Dynavax, Monderna, Meissa, NIH: DSMB Lisa Forbes Satter, MD, ADMA: Advisor/Consultant|CsL Behring: Advisor/Consultant|Grifols: Advisor/Consultant|incyte: Advisor/Consultant|Pharming: Advisor/Consultant|Takeda: Advisor/Consultant
format Online
Article
Text
id pubmed-10676883
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106768832023-11-27 546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital Stimes, Grant T Rodriguez, Brittany Gillispie, Amanda Hilliard, Tanya J Munoz, Flor M Satter, Lisa Forbes Open Forum Infect Dis Abstract BACKGROUND: Texas Children’s Hospital (TCH) implemented an outpatient clinic for eligible patients to receive infusions when COVID monoclonal antibodies (mAbs) were approved for use in non-hospitalized, high-risk patients with mild to moderate COVID-19. There are limited data evaluating the use of outpatient COVID mAbs in pediatric patients. We describe the clinical characteristics and outcomes of the patients treated with COVID mAbs at TCH. METHODS: Patients that were referred to receive COVID mAbs from 12/1/2020 to 5/5/2022 were included. Information collected included demographics, comorbidities, refusal reason, adverse events, emergency center (EC) visits or admission within 14 days after final dose, and EC visit or admission within 14 days of referral if patients did not receive COVID mAbs. Chi-square was used to determine differences between the groups. RESULTS: There were 262 patients referred during the study period. The median age of all referred patients was 15.8 years (IQR 14-17.4 years). Majority of referrals were for treatment of COVID-19 infection rather than post-exposure prophylaxis (92.8% vs 7.2%). Of the 262 referrals, 134 patients received COVID mAbs (51.2%) while 128 patients were not treated. Majority of the patients received casirivimab-imdevimab (73.9%). The comorbidities of all patients are shown in Figure 1. The most common reasons for patients to not receive COVID mAbs were no drug available or not listed, and the full list of reasons are listed in Figure 2. The median time from reported symptom onset to infusion was 4 days (IQR 2-6 days). Of the 134 infused patients, 8 patients (6%) visited the EC within 14 days from infusion, and 6 (4.5%) were admitted while 4 patients (3.1%) that did not receive an antibody visited the EC resulting in 3 admissions (2.3%) (EC visits p=0.27; admissions p=0.34). There were 11 patients (8.2%) that experienced adverse events from their infusion, which led to 5 of the 8 EC visits. Comorbidities were similar across the infused and non-infused groups (p=0.16). [Figure: see text] Number of high-risk conditions represented by all referred, high-risk patients [Figure: see text] Number of patients for each reason for not receiving a COVID-19 antibody infusion CONCLUSION: COVID mAb treatments were well tolerated among pediatric patients. Majority of patients in both groups did not require EC visit or hospitalization. More data are needed to determine the clinical efficacy of mAbs patients. DISCLOSURES: Flor M. Munoz, MD, MSc, CDC respiratory virus surveillance: Grant/Research Support|Gilead: Grant/Research Support|Moderna, sanofi, aztra zeneca, Merck, GSK: Advisor/Consultant|NIH: DSMB|NIH COVID-19 vaccines in pregnancy: Grant/Research Support|Pfizer Pediatric COVID-19 vaccines: Grant/Research Support|Pfizer, Dynavax, Monderna, Meissa, NIH: DSMB Lisa Forbes Satter, MD, ADMA: Advisor/Consultant|CsL Behring: Advisor/Consultant|Grifols: Advisor/Consultant|incyte: Advisor/Consultant|Pharming: Advisor/Consultant|Takeda: Advisor/Consultant Oxford University Press 2023-11-27 /pmc/articles/PMC10676883/ http://dx.doi.org/10.1093/ofid/ofad500.615 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Stimes, Grant T
Rodriguez, Brittany
Gillispie, Amanda
Hilliard, Tanya J
Munoz, Flor M
Satter, Lisa Forbes
546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital
title 546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital
title_full 546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital
title_fullStr 546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital
title_full_unstemmed 546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital
title_short 546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital
title_sort 546. covid-19 monoclonal antibody use at a stand alone children’s hospital
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676883/
http://dx.doi.org/10.1093/ofid/ofad500.615
work_keys_str_mv AT stimesgrantt 546covid19monoclonalantibodyuseatastandalonechildrenshospital
AT rodriguezbrittany 546covid19monoclonalantibodyuseatastandalonechildrenshospital
AT gillispieamanda 546covid19monoclonalantibodyuseatastandalonechildrenshospital
AT hilliardtanyaj 546covid19monoclonalantibodyuseatastandalonechildrenshospital
AT munozflorm 546covid19monoclonalantibodyuseatastandalonechildrenshospital
AT satterlisaforbes 546covid19monoclonalantibodyuseatastandalonechildrenshospital